After the first use of infliximab in Crohn’s Disease (CD) in 1995, the wide-scale introduction of anti-tumour necrosis factor alpha (anti-TNF alpha) medications revolutionised the treatment of inflammatory bowel diseases (IBDs) [1]. Here, TNF is linked to Crohn disease.